The double upgrade reinforces the bullish consensus, but insider selling and elevated short interest create a tug-of-war. Traders should watch for a squeeze if earnings on Aug 5 deliver upside, but the insider sales suggest caution on near-term upside.
Price Chart
Executive Summary
HSBC double-upgraded Gilead Sciences from Hold to Buy on July 6, 2026, raising its price target to $155 from $133, implying 18% upside from the current $131.27. The call is consensus-aligned: 82% of analysts rate GILD a Buy (32 of 39), with a mean target of $157.67 and a high of $180. HSBC's track record is below average at 55% accuracy on 263 calls, but the double-upgrade signals conviction. Momentum is positive with 1 upgrade and 0 downgrades in the past 30 days, and EPS revisions for the current year are trending up (3 up, 0 down in 30 days). However, insider selling by CEO O'Day ($1.9M on July 1) and a high short-interest ratio of 56.8% create a divergence with the bullish analyst signal. Earnings are due August 5, 2026, adding a near-term catalyst. The bottom line: the upgrade reinforces the bullish consensus, but traders should weigh insider sales and elevated short interest against the positive analyst momentum.
Impact Score
Consensus & Targets
Of 39 analysts covering GILD, 32 rate it Buy (11 Strong Buy, 21 Buy) and 7 rate it Hold. No Sell ratings. The consensus is strongly bullish, with 82% Buy ratings.
The mean price target is $157.67, median $160, high $180, and low $122. At $131.27, GILD trades at a 20% discount to the mean target. HSBC's $155 target is below the mean and median, placing it in the lower half of the consensus range.
Recent Analyst Activity
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| 2026-07-06 | HSBC | upgrade | Buy | $155.00 |
| 2026-06-16 | Cantor Fitzgerald | reiterate | Overweight | $155.00 |
| 2026-05-20 | Maxim Group | upgrade | Buy | $165.00 |
| 2026-05-08 | Truist Securities | reiterate | Buy | $157.00 |
| 2026-05-08 | RBC Capital | maintain | Sector Perform | $122.00 |
| 2026-04-13 | Citigroup | maintain | Buy | $165.00 |
| 2026-04-10 | Morgan Stanley | maintain | Overweight | $175.00 |
| 2026-03-10 | Jefferies | initiate | Buy | $180.00 |
| 2026-02-23 | Needham | reiterate | Buy | $170.00 |
| 2026-02-20 | Barclays | initiate | Equal-Weight | $155.00 |
In the past 30 days, there has been 1 upgrade (HSBC) and 0 downgrades. EPS revisions are mixed but slightly positive: the current-year estimate saw 3 upward revisions and 0 downward in 30 days, while the next-quarter estimate had 2 up and 0 down in 7 days. Overall, estimates are being revised modestly higher.
Firm Track Record — HSBC
HSBC accuracy: 55% on 263 calls | avg return: 5.5%
Industry benchmark: mean 51% ± 11%. Top tier: ≥61% (mean + 1σ). Based on 15 firms with ≥5 scored calls.
| Firm | Accuracy | Calls | Avg Return | vs Average |
|---|---|---|---|---|
| Truist Securities | 100% | 4/4 | 9.7% | top tier |
| TD Cowen | 100% | 2/2 | 16.2% | top tier |
| Citigroup | 100% | 2/2 | 8.3% | top tier |
| UBS | 100% | 3/3 | 11.5% | top tier |
| Mizuho | 100% | 2/2 | 16.8% | top tier |
| RBC Capital | 93% | 13/14 | 14.9% | top tier |
| Needham | 89% | 8/9 | 12.2% | top tier |
| BMO Capital | 86% | 6/7 | 7.6% | top tier |
| JP Morgan | 86% | 6/7 | 6% | top tier |
| Cantor Fitzgerald | 86% | 6/7 | 17.9% | top tier |
HSBC has a 55% accuracy rate on 263 rated stocks with an average return of 5.5%. This is below the top-tier firms covering GILD, such as RBC Capital (93% on 14 calls, 14.9% avg return) and Needham (89% on 9 calls, 12.2% avg return). The best performing firm on GILD is Mizuho (100% on 2 calls, 16.8% avg return); the worst is Piper Sandler (67% on 3 calls, 5.1% avg return).
Earnings Estimates
Next earnings: Aug 5, 2026
| Period | EPS Est. | EPS Range | Revenue | Revisions (7d) |
|---|---|---|---|---|
| 0q | $-7.14 | $-7.93 — $-3.94 | $7.4B | ↑1 ↓0 |
| +1q | $2.06 | $-0.50 — $2.57 | $7.8B | ↑2 ↓0 |
| 0y | $-0.79 | $-1.05 — $-0.63 | $30.5B | ↑1 ↓0 |
| +1y | $9.66 | $8.40 — $11.15 | $32.4B | ↑1 ↓0 |
Cross-Platform Signals
Insider trades show selling: CEO O'Day sold ~$1.9M on July 1, and other executives sold smaller amounts in June. Congressional activity is minor (two small buys by Rep. Moskowitz in May). Institutional changes are mixed: large adds by Empowered Funds (+41.8%), Walleye Capital (+552%), and MFS (+48.7%), but exits by Norges Bank and Arrowstreet Capital. Short interest is high at 56.8% of volume, indicating bearish positioning. The analyst upgrade diverges from insider selling but converges with institutional buying.
Investment Themes
Documents Analyzed
Report based on filing metadata.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 2, 2026 4w ago | Insider Cluster | $149.61 $149.05 | ▼ −0.37% | ▼ −0.04% | $144.74 (−3.26%) |
Aug 27, 2026 5w ago | Insider Cluster | $145.68 $152.21 | ▲ +4.48% | ▲ +4.22% | $144.74 (−0.65%) |
Aug 21, 2026 5w ago | Insider Cluster | $146.74 $152.67 | ▲ +4.04% | ▲ +2.73% | $144.74 (−1.36%) |
Aug 18, 2026 6w ago | Insider Cluster | $147.60 $150.89 | ▲ +2.23% | ▲ +4.18% | $144.74 (−1.94%) |
Aug 18, 2026 6w ago | Court Ruling | $143.44 $147.68 | ▲ +2.96% | ▲ +4.27% | $144.74 (+0.91%) |
Aug 13, 2026 7w ago | Court Ruling | $138.14 $143.72 | ▲ +4.04% | ▲ +5.79% | $144.74 (+4.78%) |
Aug 6, 2026 8w ago | S-3ASR | $133.21 $151.00 | ▲ +13.35% | ▲ +13.75% | $144.74 (+8.66%) |
Jul 21, 2026 10w ago | ANALYST-DOWNGRADE | $130.28 $143.44 | ▼ −10.10% | ▼ −7.54% | $144.74 (−11.10%) |
Jul 16, 2026 11w ago | Insider Cluster | $134.28 $138.33 | ▲ +3.02% | ▼ −1.43% | $144.74 (+7.79%) |
Jul 6, 2026 12w ago | ANALYST-UPGRADE | $129.61 $130.21 | ▲ +0.46% | ▲ +1.03% | $144.74 (+11.67%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access